| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $473K | — | +117.0% |
| SG&A Expense | $266K | — | -48.7% |
| Operating Income | -$739K | — | -0.3% |
| Net Income | -$725K | — | -14.4% |
| EPS (Basic) | $0.01 | — | +0.0% |
| EPS (Diluted) | $0.01 | — | +0.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $920K | -45.2% | — |
| Current Assets | $2.5M | -19.8% | — |
| Total Assets | $7.8M | -6.5% | — |
| Current Liabilities | $1.5M | +11.9% | — |
| Total Liabilities | $1.6M | +13.0% | — |
| Stockholders' Equity | $6.2M | -10.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$541K | — | -51.5% |
| Investing Cash Flow | -$217K | — | -121.7% |